Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 2/3 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Carcinoma, Non-Small-Cell Lung 361Lung Neoplasms 195Breast Neoplasms 163Ovarian Neoplasms 129Triple Negative Breast Neoplasms 79Squamous Cell Carcinoma of Head and Neck 73Small Cell Lung Carcinoma 67Fallopian Tube Neoplasms 56Head and Neck Neoplasms 46Carcinoma, Ovarian Epithelial 44Neoplasms 40Neoplasm Metastasis 39Esophageal Neoplasms 36Adenocarcinoma of Lung 36Esophageal Squamous Cell Carcinoma 29Prostatic Neoplasms 27Endometrial Neoplasms 27Uterine Cervical Neoplasms 23Brain Neoplasms 23Central Nervous System Neoplasms 22Urinary Bladder Neoplasms 21Carcinoma, Squamous Cell 21Recurrence 20Neuroblastoma 20Lymphoma, Large B-Cell, Diffuse 20Melanoma 19Lymphoma 19Carcinoma 19Adenocarcinoma, Bronchiolo-Alveolar 18Testicular Neoplasms 15

Interventions

Cisplatin 14Specimen Handling 6Cetuximab 6Surgical Procedures, Operative 5Radiotherapy, Intensity-Modulated 5Magnetic Resonance Spectroscopy 51,2-diaminocyclohexaneplatinum II citrate 5toripalimab 4Radiotherapy 4Platinum 4Docetaxel 4Celecoxib 4pembrolizumab 3X-Rays 3130-nm albumin-bound paclitaxel 3camrelizumab 2Radiotherapy, Image-Guided 2Radiation 2Paclitaxel 2Fluorouracil 2Chemoradiotherapy 2Carboplatin 2Biopsy 2tislelizumab 1sodium thiosulfate 1sacituzumab govitecan 1nimotuzumab 1nedaplatin 1merphos 1ipatasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Hypopharyngeal Neoplasms × Carboplatin × Clear all
NCT04862650 2026-02-10

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Ohio State University Comprehensive Cancer Center

Phase 2 Active not recruiting
46 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06084845 2024-07-25

Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer

Eastern Cooperative Oncology Group

Phase 2 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡